Novel Clinical Trial Designs with Dose Optimization to Improve Long-term Outcomes

Area of Science:

• Clinical trial design
• Pharmacometrics
• Oncology

Background:

• Conventional dose-finding designs for new therapies often fail to optimize patient outcomes like progression-free survival or overall survival.
• These traditional methods may select doses that are either unsafe or ineffective, leading to suboptimal treatment efficacy.
• Limitations in current designs hinder the identification of truly optimal therapeutic doses for novel treatments.

Approach:

• This study explains the limitations of conventional dose-finding methodologies in clinical trials.
• Four key recommendations are proposed: consider long-term outcomes, implement dose-screening rules, ensure adequate sample sizes, and randomize patients across doses.
• Three novel trial designs incorporating these features are illustrated, including adaptive randomization and integration of Phase I-II with Phase III trials.

Key Points:

• The first illustration involves randomizing patients between two cell therapy doses and standard of care, challenging assumptions of dose-response linearity.
• The second design expands Phase I-II by identifying candidate doses, randomizing patients, and selecting an optimal dose for maximal progression-free survival.
• The third approach integrates Phase I-II and Phase III trials, using early Phase III survival data to refine the Phase I-II dose selection.

Conclusions:

• Implementing recommended features in dose-finding designs significantly enhances the probability of selecting an optimal therapeutic dose or schedule.
• Improved dose selection through these advanced designs promises greater benefit for future patients undergoing novel therapy.
• Optimized dose-finding strategies are crucial for successful regulatory approval of new cancer treatments.